Phase 1 Sleep Disorders Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with Parkinson's disease according to a specific medical standard, where the diagnosis includes slowness of movement plus at least one other main sign (such as tremor at rest or muscle stiffness), with no other known cause for the condition
• People who received their Parkinson's disease diagnosis 4 years ago or less at the time of the screening visit
• People who are either not currently taking any standard Parkinson's medication (including levodopa, dopamine agonists, or MAO-B inhibitors) and are not expected to need such medication for around 6 months after receiving the study treatment — OR — people who have been on a stable Parkinson's medication routine for at least 3 months before the study treatment and are not expected to need dose changes for around 6 months afterward
• People with a body mass index (a measure of weight relative to height) of 35 or below at the time of the screening visit

Who may not be able to join:

• People whose medical history suggests a Parkinson's-like condition other than Parkinson's disease itself
• People with significant heart, lung, liver, kidney, digestive, hormonal, blood, psychiatric, or neurological conditions (other than Parkinson's disease) that the trial doctor believes could affect study results or raise safety concerns
• People with a history of brain or spinal disease or injury that could interfere with a lumbar puncture (a procedure to collect fluid from around the spine) or the flow of that fluid
• People for whom a brain MRI scan is not medically appropriate
• People with a known allergy or sensitivity to lidocaine, a local anaesthetic
• People who have previously had a bad reaction to an injection into the spinal fluid
• People with a current history of bleeding or clotting problems that would increase the risk of bleeding during a lumbar puncture
• People who have previously had gene therapy, cell therapy, or surgery for Parkinson's disease, including deep brain stimulation

Important: These are not all of the trial's eligibility criteria. Always verify eligibility with the trial site directly before applying.